Introduction {#Sec1}
============

Most people with coronavirus infectious disease-2019 (COVID-19) have mild to moderate symptoms and recover after the appropriate medical intervention(s). However, 15--32 percent develop severe or critical COVID-19 with a case-fatality rate of 1--15% \[[@CR1]--[@CR6]\]. There are few data of hematological abnormalities in persons with COVID-19 \[[@CR7]--[@CR13]\]. We studied hematological co-variates in 1449 hospitalized persons with COVID-19 in five hospitals in Wuhan, China, interrogating correlations of admission parameters with COVID-19 outcomes.

Methods {#Sec2}
=======

Study design and subjects {#Sec3}
-------------------------

We studied subjects in seven centers of five hospitals of Union Hospital (Central Hospital, Union West Hospital, and Union Tumor Hospital), Wuhan Central Hospital, General Hospital of Central Theater Command, PLA, Wuhan Third Hospital, and Wuhan Jin-Yin-Tan Hospital between January 20, and April 4, 2020. Subjects were studied on admission for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infection by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) of nasal and pharyngeal swabs and/or blood test for anti-SARS-CoV-2 IgG/IgM antibodies using a colloidal-gold-based 2019-nCoV IgG/IgM Detection Kit (Nanjing Vazyme Medical Technology, Nanjing, China). COVID-19 was diagnosed according to World Health Organization interim guidance and the Novel Coronavirus Pneumonia Diagnosis and Treatment Program of the National Health Commission of China \[[@CR14], [@CR15]\]. Severity of COVID-19 was graded as follows: (1) mild; mild clinical symptoms, no pneumonia on lung CT; (2) common: fever, cough and lung CT with pneumonia; (3) severe: respiratory distress (respiratory rate \> 30 min^−1^, oxygen saturation (O~2Sat~) ≤ 93 percent at rest and/or ratio of arterial oxygen partial pressure to fractional inspired oxygen ≤300 mmHg (P~aO2~/F~IO2~); and (4) critical: aforementioned criteria of respiratory failure receiving mechanical ventilation, shock, and/or organ failure other than lung and/or intensive care unit (ICU) hospitalization \[[@CR12], [@CR15]\]. Subjects were treated as described below or according to Chinese government guidelines \[[@CR15]--[@CR18]\]. The study was approved by the Ethics Committees of Union Hospital (2020-0095) and of Wuhan Central Hospital (2020-007). Written and oral informed consent from subjects was waived by the Ethics Committees.

Data collection {#Sec4}
---------------

Electronic medical records of subjects including epidemiological, demographic, and laboratory data. Outcomes included: (1) death; (2) alive with two successive negative SARS-Cov-2 qRT-PCR tests; (3) interval from symptoms to hospital admission, discharge, or death; (4) negative qRT-PCT test; and (5) interval from admission to COVID-19 progression. Data collection forms were reviewed and verified independently by two researchers. A third researcher adjudicated discordances.

Statistical analysis {#Sec5}
--------------------

Categorical variables were described as frequency rates and percentages and continuous variables by median and interquartile range (IQR). Significance was tested by Kruskal--Wallis test or the Fisher exact test. A two-sided *P* \< 0.05 was considered significant. Locally weighted regression and smoothing scatterplot was performed to equate a smooth curve about the relationship between time and values of laboratory parameters. Uni- and multivariable logistic regression models were used to interrogate co-variates associated with in-hospital death. Analyses were not been adjusted for multiple comparisons. Data were analyzed as of April 4, 2020.

Results {#Sec6}
=======

Baseline co-variates corelated with death from COVID-19 {#Sec7}
-------------------------------------------------------

We analyzed data from 3559 consecutive subjects. One thousand seven hundred were excluded because of missing data of SARS-CoV-2 qRT-PCR or anti-SARS-CoV-2 IgG/IgM, 410 with co-morbidities and/or receiving drugs that would potentially affect bone marrow function (Supplementary Fig. [1](#MOESM1){ref-type="media"}). The resulting study cohort was 1449 subjects.

Seven hundred and thirty-three subjects (51%) were male. Median age was 57 years (IQR, 42--66 years), 576 (40%) were 60--79 years and 66 (5%), ≥80 years. Common signs and symptoms on admission included dry (485; 43%) or productive cough (551; 38%), fatigue (531; 37%), and shortness of breath (520; 37%). Eighty three subjects (6%) were smokers and 71 (6%), health care providers. Four subjects were exposed in the Hunan Wholesale Seafood Market and 94 (6%), close contact with persons with SARS-CoV-2-infection. Twenty nine subjects (2%) had mild COVID-19, 956 (66%), moderate, 347 (24%), severe and 117 (8%), critical. Lung computed tomography (CT) scan showed bilateral pneumonia in 1215 (87%), ground-glass opacity in 1041 (75%), patchy shadows in 579 (42%), and consolidation in 242 (18%). Eight hundred and twenty-six (57%) subjects had ≥1 abnormal liver function tests. One hundred and forty-four (10%), acute respiratory distress syndrome (ARDS) and 392 (27%), bacterial co-infections. Other complications had \<10% frequencies including heart, acute kidney abnormalities, septic shock, and multiple organ failure. One hundred and fifty-six subjects (14%) received high-flow nasal cannula oxygen, 98 (7%), noninvasive ventilation (no intubation), 54 (4%), invasive ventilation (intubation), and four extracorporeal membrane oxygenation (ECMO). Median ICU stay was 12 days (IQR, 5--21 days). Median intervals from symptom onset to a negative SARS-CoV-2 qRT-PCR RNA, progression and death or discharge were 22 days (IQR 17--28 days), 10 days (IQR 7--14 days), and 30 days (IQR 23--37 days).

At the time of data lock 1327 (92%) subjects were alive and discharged; 122 (8%), died (Table [1](#Tab1){ref-type="table"}). Subjects who died were significantly older than survivors (median 69 versus 55 years; *P* \< 0.001) and more likely male (74% versus 48%; *P* \< 0.001), with more frequent fatigue (54% versus 35%; *P* \< 0.001), chills (26% versus 15%; *P* \< 0.001), productive cough (50% versus 37%, *P* = 0.006), shortness of breath (66% versus 35%; *P* \< 0.001), a higher temperature on admission (median 36.8 °C; IQR 36.5--37.8 °C versus median 36.6 °C; IQR 36.4--37.0 °C; *P* \< 0.001), bilateral pneumonia (95% versus 86%; *P* = 0.01), and/or consolidation (35% versus 16%, *P* \< 0.001) on lung CT scan but similar dry cough (44% versus 43%, *P* = 0.824), diarrhea (both 13%*; P* = 0.897), and myalgia (20% versus 17%; *P* = 0.502).Table 1Baseline characteristics of survivors and non-survivors with COVID-19.Total\
*n* = 1449Alive\
*n* = 1327Died\
*n* = 122*P* valueCharacteristicsAge, median (IQR), years57 (42, 66)55 (41, 65)69 (63, 78)\<0.001Age distribution \<40 years306 (21)305 (23)1 (0.8) 40--59 years501 (35)481 (36)20 (16) 60--79 years576 (40)499 (38)77 (63) ≥80 years66 (5)42 (3)24 (20)Female sex716 (49)684 (52)32 (26)\<0.001Smoking history83 (6)66 (5)17 (15)\<0.001Health care provider71 (6)69 (7)2 (2)0.038Exposure history0.026 Huanan Seafood Market4 (0.28)2 (0.15)2 (2) Close contact with patients94 (6)89 (7)5 (4)Signs and symptoms Temperature (°C)36.7 (36.4, 37.1)36.6 (36.4, 37.0)36.8 (36.5, 37.8)\<0.001 Shortness of breath520 (37)456 (35)64 (66)\<0.001 Dry cough485 (43)437 (43)48 (44)0.824 Wet cough551 (38)491 (37)60 (50)0.006 Fatigue531 (37)466 (35)65 (54)\<0.001 Nausea or vomiting88 (6)83 (6)5 (4)0.43 Diarrhea186 (13)170 (13)16 (13)0.897 Chill226 (16)194 (15)32 (26)\<0.001 Runny nose30 (2)28 (2)2 (1.6)0.999 Myalgia255 (18)231 (17)24 (20)0.502 Headache89 (6)84 (6)5 (4)0.43Staging\<0.001 Mild29 (2)29 (2)0 (0) Moderate956 (66)951 (72)5 (4) Severe347 (24)332 (25)15 (12) Critical117 (8)15 (1)102 (84)Imaging features Bilateral pneumonia1215 (87)1117 (86)98 (95)0.01 Consolidation242 (18)207 (16)35 (35)\<0.001 Ground-glass opacity1041 (75)974 (76)67 (67)0.059 Patchy shadows579 (42)532 (41)47 (47)0.218Complications ARDS144 (10)37 (3)107 (88)\<0.001 Bacterial infections392 (27)288 (22)104 (85)\<0.001 Septic shock45 (4)1 (0.1)44 (40)\<0.001 Acute kidney injury49 (3)7 (0.5)42 (34)\<0.001 Cardiac injury125 (9)58 (4)67 (55)\<0.001 Liver damage826 (57)721 (54)105 (86)\<0.001 Gastrointestinal bleeding20 (1)4 (0.3)16 (13)\<0.001 Coagulopathy28 (2)0 (0)28 (23)\<0.001 Multiple organ failure72 (5)3 (0.2)69 (57)\<0.001Treatments Antibiotics1203 (85)1084 (83)119 (98)\<0.001 Antimycotics44 (3)17 (1)27 (22)\<0.001 Oseltamivir604 (42)564 (43)40 (33)0.037 Umifenovir1099 (76)1004 (76)95 (78)0.688 Lopinavir and Ritonavir276 (24)232 (23)44 (40)\<0.001 Interferon297 (21)269 (20)28 (23)0.483 Corticosteroids576 (40)471 (35)105 (86)\<0.001 Intravenous immunoglobin381 (28)314 (25)67 (55)\<0.001 High-flow nasal cannula oxygen therapy156 (14)59 (6)97 (88)\<0.001 Noninvasive mechanical ventilation98 (7)21 (2)77 (63)\<0.001 Invasive mechanical ventilation54 (4)7 (0.5)47 (39)\<0.001 ECMO4 (0.4)1 (0.1)3 (3)0.003Outcomes ICU admission63 (4)23 (2)40 (33)\<0.001 Time from illness onset to ICU admission, median (IQR), days14 (10, 19)10 (8, 18)15 (12, 20)0.141 ICU length of stay, median (IQR), days12 (5, 21)11 (8, 21)12 (4, 21)0.619 Time from illness onset to repeated negatively tests of SARS-CoV-2, median (IQR), days22 (17, 28)22 (17, 28)19 (12, 26)0.066 Time from illness onset to admission, median (IQR), days10 (7, 15)10 (7, 16)10 (7, 12)0.017 Time from illness onset to progression, median (IQR), days10 (7, 14)10 (6, 14)12 (9, 19)0.001 Time from illness onset to outcome, median (IQR), days30 (23, 37)30 (24, 38)21 (15, 29)\<0.001 Time from diagnosis to outcome, median (IQR), days19 (13, 27)20 (13, 27)11 (5, 17)\<0.001 Time from admission to outcome, median (IQR), days18 (13, 23)18 (13, 23)11 (6, 20)\<0.001*IQR* interquartile ranges, *ARDS* acute respiratory distress syndrome, *ECMO* extracorporeal membrane oxygenation, *ICU* intensive care unit, *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2.

Median interval from symptom(s) onset to admission was 10 days in survivors (IQR 7--16 days) versus 10 days (IQR 7--12 days; *P* = 0.017) in non-survivors. Median interval from admission to progression in survivors was briefer (10 days \[IQR 6--14 days\] versus 12 days \[IQR 9--19; *P* = 0.001). Median interval from onset to ICU admission was 14 days (IQR 10--19 days) and median ICU stay, 12 days (IQR 5--21 days) with no significate difference between survivors and non-survivors (*P* = 0.141 and *P* = 0.619). Subjects who died were more likely to have complications (122 \[100%\] versus 741 \[56%\]; *P* \< 0.001) including acute respiratory distress syndrome (ARDS; 107 \[88%\] versus 37 \[3%\]; *P* \< 0.001), liver function test abnormalities (105 \[86%\] versus 721 \[54%\]; *P* \< 0.001) and bacterial infections (104 \[85%\] versus 288 \[22%\]; *P* \< 0.001). More subjects dying received high-flow nasal cannula oxygen therapy (97 \[88%\] versus 59 \[6%\]; *P* \< 0.001). Four subjects received ECMO including one survivor.

Blood hematological co-variates of survivors and non-survivors {#Sec8}
--------------------------------------------------------------

We first compared admission hematological co-variates between survivors and non-survivors. Subjects who died had a higher median WBC (8 × 10E + 9/L \[IQR 6--11 × 10E + 9/L\] versus 5 × 10E + 9/L \[IQR 4--7 × 10E + 9/L\]; *P* \< 0.001), higher median neutrophils (7 × 10E + 9/L \[IQR 5--10 × 10E + 9/L\] versus 3 × 10E + 9/L \[IQR 2--4 ×10E + 9/L\]; *P* \< 0.001), lower median lymphocytes (0.5 × 10E + 9/L \[IQR 0.4--0.8 × 10E + 9/L\] versus 1.2 × 10E + 9/L \[IQR 0.9--1.7 × 10E + 9/L\]; *P* \< 0.001) and lower median platelets (166 × 10E + 9/L \[IQR 109--223 × 10E + 9/L\] versus 208 × 10E + 9/L \[IQR 164--268 × 10E + 9/L\]; *P* \< 0.001) compared with survivors (Table [2](#Tab2){ref-type="table"}).Table 2Blood hematological co-variates of survivors and non-survivors with COVID-19.*N*TotalAliveDied*P* valueHemoglobin, g/L (115--150) Baseline1437129 (119--139)128 (119--139)131 (122--143)0.068 Max1101132 (122--142)131 (126--146)136 (122--142)0.049 Min1101119 (108--131)120 (110--131)105 (78--126)\<0.001White blood cell, ×10E + 9/L (3.5--10) Baseline14205 (4--7)5 (4--7)8 (6--11)\<0.001 Max14217 (5--9)7 (5--8)16 (12--21)\<0.001 Min14215 (4--6)5 (4--6)6 (4--9)\<0.001Neutrophil, ×10E + 9/L (1.8--6.3) Baseline14173 (2--5)3 (2--4)7 (5--10)\<0.001 Max14215 (3--7)4 (3--6)14 (11--20)\<0.001 Min14213 (2--4)3 (2--4)5 (3--8)\<0.001Lymphocyte, ×10E + 9/L (1.1--3.2) Baseline14401.2 (0.8--1.6)1.2 (0.9--1.7)0.5 (0.4--0.8)\<0.001 Min14111.0 (0.7--1.4)1.1 (0.8--1.5)0.3 (0.2--0.5)\<0.001Monocyte, ×10E + 9/L (0.1--0.6) Baseline14080.4 (0.3--0.53)0.4 (0.3--0.5)0.3 (0.2--0.5)\<0.001 Max14190.5 (0.4--0.7)0.5 (0.4--0.7)0.5 (0.4--0.8)0.305 Min14190.3 (0.2--0.4)0.3 (0.3--0.4)0.2 (0.1--0.3)\<0.001Platelet, ×10^9^ E + 9/L (125--350) Baseline1415206 (159--264)208 (164--268)166 (109--223)\<0.001 Max1420258 (204--325)263 (208--331)190 (134--255)\<0.001 Min1420176 (135--224)180 (143--226)80 (39--147)\<0.001Data are presented as medians (interquartile ranges, IQR). *p* values were calculated by Mann--Whitney *U* test, *χ*² test, or Fisher's exact test, as appropriate.

### Blood lymphocyte subsets {#Sec9}

We next analyzed baseline blood lymphocyte subsets between subjects who died and survivors (Table [3](#Tab3){ref-type="table"}). Subjects who died had lower median CD3-positive cells (140 × 10E + 9/L \[IQR 75--190 × 10E + 9/L\] versus 381 × 10E + 9/L \[IQR 2--918 × 10E + 9/L\]; *P* = 0.023), CD3-positive/CD4-positive cells (71 × 10E + 9/L \[IQR 46--107 × 10E + 9/L\] versus 227 × 10E + 9/L \[IQR 1--487 × 10E + 9/L\]; *P* = 0.036), CD3-positive/CD8-positive cells (49 × 10E + 9/L \[IQR 14--64 × 10E + 9/L\] versus 141 × 10E + 9/L \[IQR, 1--308 × 10E + 9/L\]; *P* = 0.023) and lower median proportions of CD3-positive cells (59% \[IQR 50--67%\] versus 72% \[IQR 63--78%\]; *P* \< 0.001), median proportions of CD3-positive/CD8-positive cells (14% \[IQR 10--18%\] versus 24% \[IQR 19--30%\]; *P* \< 0.001) and median proportions of B cells (16% \[IQR 10--28%\] versus 12% \[IQR 9--17%\]; *P* = 0.022). There were no significant differences in median proportions of CD3-positive/CD4-positive T- or natural-killer (NK)-cells, nor in concentrations of B cells or NK-cells between survivors and non-survivors.Table 3The lymphocyte subsets of peripheral blood in of survivors and non-survivors with COVID-19.Lymphocyte subset*N*TotalAliveDied*P* valueCD3+ (%)57972 (62--78)72 (63--78)59 (50--67)\<0.001CD3 concentration × 10E + 9/L246359 (2--901)381 (2--918)140 (75--190)0.023CD3+CD4+ (%)57941 (33--48)41 (33--48)37 (28--48)0.443CD3+CD4+ concentration × 10E + 9/L246200 (1--481)227 (1--487)71 (46--107)0.036CD3+CD8+ (%)57923 (18--30)24 (19--30)14 (10--18)\<0.001CD3+CD8+ concentration × 10E + 9/L246119 (1--302)141 (1--308)49 (14--64)0.023NK cell (%)41510 (6--17)10 (6--17)10 (5--12)0.29NK cell concentration × 10E + 9/L24676 (0.4--185)77 (0.4--188)41 (19--102)0.453B lymphocyte (%)41513 (9--18)12 (9--17)16 (10--28)0.022B lymphocyte concentration × 10E + 9/L24696 (0.3--178)98 (0.3--188)55 (22--91)0.136CD4+/CD8+ ratioMax5772 (1.4--2.6)1.9 (1.4--2.6)3.0 (1.9--4.5)\<0.001Min4891.6 (1.2--2)1.57 (1.2--2)1.6 (1.3--2.3)0.336Data are median (IQR), *n* (%), or *n*/*N* (%). Cell count at presentation (cells/ul). *p* values were calculated by Mann--Whitney *U* test, *χ*^2^ test, or Fisher's exact test, as appropriate.*NK* *cell *natural killer cell

### Clotting co-variates {#Sec10}

Baseline and maximum values of prothrombin time, activated partial thromboplastin time, and D-dimer concentrations were significantly higher in subjects who died compared with survivors. In contrast, fibrinogen concentration was higher at baseline in subject who died (median 4.3 g/L \[IQR, 3.2--5.2 g/L\] versus 3.6 g/L \[IQR 2.9--4.5 g/L); *P* \< 0.001) but had lower minimum values (2.6 g/L \[IQR 1.7--3.9 g/L\] versus 3.2 g/L \[IQR 2.6--3.9 g/L\]; *P* \< 0.001; Table [4](#Tab4){ref-type="table"}).Table 4Clotting factor levels of survivors and non-survivors with COVID-19.*N*TotalAliveDied*P* valuePT, s (11--16) Baseline105513 (12--13)13 (12--13)14 (13--15)\<0.001 Max103513 (12--14)13 (12--14)17 (14--20)\<0.001APTT, s (28--43.5) Baseline105534 (30--38)34 (30--37)35 (300--40)0.019 Max128934 (30--38)34 (30--37)40 (34--50)\<0.001D-dimer, mg/L (\<0.5) Baseline12390.4 (0.2--0.9)0.4 (0.2--0.8)3.6 (0.9--8)\<0.001 Max12620.6 (0.2--1.6)0.5 (0.2--1)8 (6--8)\<0.001Fibrinogen, g/L (2--4) Baseline13043.7 (2.9--4.6)3.6 (2.9--4.5)4.3 (3.2--5.2)\<0.001 Min9763.2 (2.5--3.9)3.2 (2.6--3.9)2.6 (1.7--3.9)\<0.001*PT* prothrombin time, *APTT* activated partial thromboplastin time.

### Inflammatory and biochemical co-variates {#Sec11}

Median admission concentrations of C-reactive protein (CRP) (93 mg/L \[IQR 58--125 mg/L\] versus 9 mg/L \[IQR 3--30 mg/L\]; *P* \< 0.001), procalcitonin (0.2 ng/ml \[IQR 0.12--0.6 ng/ml\] versus 0.05 ng/ml \[IQR 0.04--0.1 ng/ml\]; *P* \< 0.001) and lactate dehydrogenase (LDH) (470 U/L \[IQR 359--599 U/L\] versus 199 U/L \[IQR 161--258 U/L\]; *P* \< 0.001) were significantly higher in subjects who died compared with survivors (Table [5](#Tab5){ref-type="table"}). Subjects who died were more likely to have abnormal heart, liver, and/or kidney function and to have higher admission median concentrations of interleukin-6 (IL-6; 71 pg/ml \[IQR 29--442 pg/ml\] versus 9 pg/ml \[IQR 4--30 pg/ml\]; *P* \< 0.001) and interleukin-10 (IL-10; 11 pg/ml IQR \[6--30 pg/ml\] versus 4 pg/ml \[IQR 3--5 pg/ml\]; *P* \< 0.001). There were no significant differences in concentrations of interleukins-2 (IL-2) or -4 (IL-4), tumor necrosis factor (TNF)-α, or interferon (IFN)-γ between survivors and non-survivors.Table 5Biochemical parameters and inflammatory cytokines of survivors and non-survivors with COVID-19.*N*TotalAliveDied*P* valueCRP, mg/L (\<8) Baseline104611 (3, 44)9 (3, 30)93 (58, 125)\<0.001 Max106314 (4, 55)11 (3, 38)140 (110, 181)\<0.001Procalcitonin, ng/ml (\<0.5) Baseline12730.05 (0.05, 0.1)0.05 (0.04, 0.1)0.2 (0.12, 0.6)\<0.001 Max10650.07 (0.04, 0.1)0.06 (0.04, 0.1)1.2 (0.4, 4)\<0.001LDH, U/L (109--245) Baseline1338207 (165, 283)199 (161, 258)470 (359, 599)\<0.001 Max1354215 (174, 302)207 (169, 271)707 (509, 1154)\<0.001Ferritin, ng/ml (4.6--204)231542 (226, 1207)446 (191, 906)1584 (1196, 2000)\<0.001ALT, U/L (5--35)142939 (22, 68)37 (21, 66)62 (34, 150)\<0.001AST, U/L (8--40)142831 (22, 49)30 (22, 44)68 (45, 143)\<0.001Total bilirubin, μmol/L (5.1--19)124514 (10, 19)13 (10, 17)25 (16, 39)\<0.001Creatine kinase, U/L (26--140)115187 (54, 150)81 (52, 130)253 (104, 656)\<0.001BNP, pg/ml (\<100)62750 (14, 160)39 (12, 115)454 (116, 1377)\<0.001Myoglobin, ng/ml (\<140)71832 (21, 60)29 (21, 49)476 (147, 1200)\<0.001Troponin I, ng/L (\<26.2)8303 (1, 10)2 (0.9, 7)212 (48, 1011)\<0.001BUN, mmol/L (2.9--8.2)14145 (4, 6)5 (4, 6)14 (8, 23)\<0.001Scr, μmol/L (44--106)141470 (59, 83)69 (59, 81)100 (71, 211)\<0.001IL-2, pg/ml (0.1--4.1)3443 (3, 4)3 (3, 4)3 (3, 5)0.849IL-4, pg/ml (0.1--3.2)3803 (2, 4)3 (2, 4)2 (2, 4)0.804IL-6, pg/ml (0.1--2.9)65910 (4, 37)9 (4, 30)71 (29, 442)\<0.001IL-10, pg/ml (0.1--5)3804 (3, 6)4 (3, 5)11 (6, 30)\<0.001TNF α, pg/ml (0.1--23)3803 (2, 6)4 (2, 6)3 (2, 4)0.183IFN γ, pg/ml (0.1--18)3803 (2, 4)3 (2, 4)3 (2, 4)0.88*CRP* C-reactive protein, *LDH* lactate dehydrogenase, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *BNP* brain natriuretic peptide, *BUN* blood urea nitrogen, *Scr* serum creatinine, *IL* interleukin, *TNF* tumor necrosis factor, *IFN* interferon.

Dynamic changes in hematological co-variate {#Sec12}
-------------------------------------------

Next, we studied dynamic changes in hematological co-variates between survivors and non-survivors in 390 subjects from Wuhan Third Hospital with daily determinations (Supplementary Table [1](#MOESM1){ref-type="media"}). Subjects who died had higher concentrations of WBCs, neutrophils, D-dimmer, PT, LDH, and CRP but lower concentrations of lymphocytes and platelets throughout their hospitalization. These dynamic changes are displayed in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Dynamic changes of hematological variables in patients with COVID-19 during hospitalization.The *Y*-axis "value" include units of all above data: ×10E + 9/L for white bloods cells, neutrophils, lymphocytes, monocytes, and platelets; g/L for hemoglobin, fibrinogen (FIB); mg/L for D-dimer; s for prothrombin time (PT), activated partial thromboplastin time (APTT); U/L for lactate dehydrogenase (LDH); ng/ml for procalcitonin (PCT); mg/L for C-reactive protein (CRP). Data are presented as medians (interquartile ranges, IQR).

Uni- and multivariable analyses {#Sec13}
-------------------------------

We analyzed admission hematological co-variates and their multiple measurements considering changes (Δ = Max − Min, Max − baseline, or baseline − Min) correlated with risk of death in all subjects (Supplementary Table [2](#MOESM1){ref-type="media"}). In a multivariable logistic regression model, age (Odds Ratio \[OR\] = 1.18 \[1.02, 1.36\]; *P* = 0.026), baseline D-dimer (OR = 3.18 \[1.48, 6.82\]; *P* = 0.003), Δ fibrinogen (OR = 6.45 \[1.31, 31.69\]; *P* = 0.022), Δ platelets (OR = 0.95 \[0.90--0.99\]; *P* = 0.029), Δ CRP (OR = 1.09 \[1.01, 1.18\]; *P* = 0.037) and Δ LDH (OR = 1.03 \[1.01, 1.06\]; *P* = 0.007) correlated with an increased risk of death (Table [6](#Tab6){ref-type="table"}).Table 6Multivariate analysis of hematological co-variates associated with in-hospital death of patients with COVID-19.Odds Ratio95% Confidence Interval*P* valueAge (years)1.18(1.02--1.36)0.026Baseline D-dimer (mg/L)3.18(1.48--6.82)0.003Δ Platelet (×10E + 9/L)^a^0.95(0.90--0.99)0.029Δ Neutrophil (×10E + 9/L)^a^1.31(0.99--1.72)0.058Δ Fibrinogen (g/L)^b^6.45(1.31--31.69)0.022Δ C-reactive protein (mg/L)^c^1.09(1.01--1.18)0.037Δ Lactate dehydrogenase (U/L)^c^1.03(1.01--1.06)0.007^a^Δ = Max − Min.^b^Δ = baseline − Min.^c^Δ = Max − baseline.

Discussion {#Sec14}
==========

Our data indicate two baseline co-variates (age and D-dimer) on admission and four dynamic co-variates (Δs of concentrations of CRP, LDH, fibrinogen, and platelets) correlate with an increased risk of death in almost 1500 hospitalized persons with COVID-19. In our dataset, we could not confirm other co-variates such as male sex \[[@CR19]\], and comorbidities of atherosclerotic cardiovascular disease \[[@CR20]\] and hypertension \[[@CR21]\] that had been excluded from the present study.

Two admission co-variates correlated with risk of death: age and D-dimer concentration. Similar correlates are reported by others in COVID-19 \[[@CR8], [@CR19], [@CR20], [@CR22]--[@CR24]\] and in two other coronavirus infections, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome \[[@CR25], [@CR26]\]. Age related immune deficiency may be the explanation of this association but is unproved \[[@CR27]\]. High D-dimer concentration may result from the inflammation associated with COVID-19 and subsequent activation of coagulation \[[@CR28]\]. Several potential risk factors during hospitalization, including disseminated intra-vascular coagulation, infection, dehydration, prolonged immobilization, mechanical ventilation, and central venous catheter use may further increase D-dimer concentrations \[[@CR29], [@CR30]\].

Four dynamic co-variates correlated with an increased risk of death including Δs of concentrations of CRP, LDH, fibrinogen, and platelets. Similar data are rarely reported in COVID-19-infection \[[@CR7], [@CR8], [@CR31]\]. Higher admission LDH concentration was reported to be a risk factor for death by different studies \[[@CR19], [@CR23], [@CR32]\]. However, we found the dynamics were more predictive. Han et al. report a dynamic decrease of CRP concentration in 17 subjects with COVID-19 who recovered \[[@CR31]\]. There are few data on dynamics of fibrinogen concentration in persons with COVID-19. Tang et al. reported differences in dynamic fibrinogen between survivor and non-survivors, but this dynamic co-variate was not identified to be a risk factor for death \[[@CR7]\]. Admission and dynamic platelets are not reported to correlate with risk of death in persons with COVID-19 \[[@CR22], [@CR33], [@CR34]\].

Our study has important limitations. It was retrospective and researchers were not blinded to the outcome when they analyzed the data. Also, we have no external validation cohort. Finally, we did not adjust for multiple comparisons. As such, our conclusions should be interpreted as exploratory and descriptive. Because subjects more likely to die have profound changes in several of these co-variates the correlations we report should not be assumed to be *cause-and-effect*.

In conclusion, we show admission hematological co-variates except D-dimer concentration are not associated with an increased risk of death in a large cohort of subjects with COVID-19. However, dynamic measurements of platelets, fibrinogen, CRP, and LDH correlate with risk of death. We await validation of our conclusions.
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